CENTRAL FAX CENTER

NO. 5747 P. 1

SEP 0 8 2005

Attorney's Docket No.: 10797-004005

OFFICIAL COMMUNICATION FACSIMILE:

OFFICIAL FAX NO: (571) 273-8300

Number of pages including this page

Applicant: Ann M. Lees et al.

TEST

Art Unit: 1644

Serial No.: 10/616,187

Examiner: Jo Ann Rinaudo

Filed

: July 9, 2003

Title

: NOVEL LOW DENSITY LIPOPROTEIN BINDING PROTEINS AND THEIR

USE IN DIAGNOSING AND TREATING ATHEROSCLEROSIS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attached to this facsimile communication cover sheet is a Response to Restriction Requirement, faxed this 8th day of September, 2005, to the United States Patent and Trademark Office.

Respectfully submitted,

Date: September 8, 2005

Reg. No. 47,443

Fish & Richardson P.C. Citigroup Center 52nd Floor 153 East 53rd Street New York, New York 10022-4611

Telephone: (212) 765-5070

Fax: (212) 258-2291

30247914.doc

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (212) 765-5070 to arrange for its return. Thank you.

RECEIVED **CENTRAL FAX CENTER**

SEP 0 8 2005

Attorney's Docket No.: 10797-004005

P. 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ann M. Lees et al.

Art Unit: 1644

Serial No.: 10/616,187

Filed

Examiner: Jo Ann Rinaudo

Title

: July 9, 2003

: NOVEL LOW DENSITY LIPOPROTEIN BINDING PROTEINS AND THEIR

USE IN DIAGNOSING AND TREATING ATHEROSCLEROSIS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated August 8, 2005, applicants elect the invention of Group II, drawn to antibodies that bind to the polypeptide of SEQ ID NO:43. The election is made with traverse.

Applicants respectfully request that the claims of Group IV be examined together with the claims of elected Group II.

The claims of Group II are directed to antibodies that bind to the human LBP-2 sequence of SEQ ID NO:43. Human LBP-2 is described in both SEQ ID NO:43 (full length polypeptide) and SEQ ID NO:7 (Group IV; fragment of human LBP-2). Because of the relatedness of the human LBP-2 sequences of SEQ ID NO:43 and SEQ ID NO:7, the issues raised during examination of antibodies directed against the sequences are expected to be similar, thereby facilitating simultaneous examination of the anti-human LBP-2 antibodies.

In light of the above comments, applicants request that the Examiner examine all of the claims directed to antibodies that bind to the human LBP-2 sequences of SEQ ID NO:43 or SEQ **ID** NO:7.

CERTIFICATE OF TRANSMISSION BY FACSIMILE

1 hereby certify that this correspondence is being transmitted before the Patent and Trademark Office on the date indicate below.
September 8, 2005
Date of Transmission
Signature Juk Brennan

NO. 5747 P.

\$EP. 8.2005 5:30PM

TEST

Attorney's Docket No.: 10797-004005

Applicant: Ann M. Lees et al.

Serial No.: 10/616,187 Filed: July 9, 2003 Page: 2 of 2

Applicants reserve the right to rejoin the method claims of one or more of non-elected

Groups VI and/or VIII upon allowance of the claims of Group II (and Group IV).

Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 10797-004005.

Respectfully submitted,

Date: September 8, 4005

Jack Brennan Reg. No. 47,443

Fish & Richardson P.C. Citigroup Center 52nd Floor 153 East 53rd Street

New York, New York 10022-4611

Telephone: (212) 765-5070 Facsimile: (212) 258-2291

30247907.doc